SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 5/10
Horizonweeks Processed14d 16h ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

Monitor the December 4 shareholder vote and any updates on the private placement financing. The CVR milestones for nebokitug in RA will be a key value driver post-merger.

DirectionNeutral
Confidencehigh
Horizonweeks

nebokitug

◆ Mixed Named in this press release
Impact
Phase
Phase 2 (complete); preparing Phase 3
Time to market
At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
Next catalyst
None dated

What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.18
T+0 close · Nov 2, 2026 · via day close
Latest settled
+11.02%
T+5 · $1.31 · next T+20 in 14d
Vs SPY
+10.94%
α at T+5
Latest observation
+38.53%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $1.18entry
  2. T+1 · 14d ago 0.00%α −0.30% · $1.18
  3. T+5 · 8d ago +11.02%α +10.94% · $1.31
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics announced that the SEC declared effective the S-4 registration statement for its proposed merger with Scipher Medicine Corporation. A special shareholder meeting to vote on the merger is scheduled for December 4, 2026, with closing expected in early 2027. Upon closing, pre-merger Chemomab equity holders will own approximately 32% of the combined company and will receive contingent value rights tied to nebokitug milestones.

Key Facts

  • SEC declared effective the S-4 registration statement for the Chemomab/Scipher merger on October 30, 2026.
  • Special meeting of Chemomab shareholders to vote on the merger is scheduled for December 4, 2026.
  • Closing expected in early 2027, subject to shareholder approval, redomiciling to the U.S., and other customary conditions.
  • Pre-merger Chemomab equity holders will own approximately 32% of the combined company; Scipher holders will own approximately 68%.
  • Chemomab shareholders will receive contingent value rights (CVRs) tied to nebokitug milestones.
  • Combined company will be named Scipher Medicine Corporation and trade under ticker SCIP on Nasdaq.
  • Shareholders representing ~20% of Chemomab voting power have entered into voting support agreements in favor of the merger.
  • Combined company plans to initiate a Phase 2 trial of nebokitug in rheumatoid arthritis in H1 2027, with readout in 2028.

Financial Impact

Pre-merger Chemomab holders to own ~32% of combined company; CVRs provide additional contingent value. No dollar values stated.

ownershipdilution

Risk Factors

  • Shareholder approval not obtained or closing conditions not satisfied.
  • Delays in clinical trial initiation or readout for nebokitug.
  • Combined company may require additional capital to fund operations and trials.
  • Market cap of $9M suggests high risk and volatility; any delay or negative news could have outsized impact.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393077

Track record

15 reports on CMMB

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  2. Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  3. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $1.18 Now $1.62 +37.29% settles Jan 29
  5. Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  6. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
  7. Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
  8. Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
  9. Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
  10. Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 9h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026